• TAVR with Self-Expanding Prosthesis Safe, Effective In Low-Risk Patients with Bicuspid Aortic Valves

    Transcatheter aortic valve replacement (TAVR) using a self-expanding prosthesis is safe in low-risk patients with bicuspid aortic stenosis, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

    Basel Ramlawi, MD, a cardiothoracic surgeon and chairman of The Heart & Vascular Center at Valley Health System in Virginia, presented the results on behalf of the Medtronic Low-Risk Bicuspid investigators.

    The prospective registry enrolled 150 patients at 25 high-volume centers across the U.S. Enrolled patients had an average age of 70 years and a Society of Thoracic Surgery (STS) mortality risk score of 1.4%. Patients with Sievers type 0 and 1 bicuspid valves were included.

    Patients were treated with Medtronic’s Evolut R (23, 26, 29 or 34 mm) or the Evolut PRO (23, 26 or 29 mm) self-expanding transcatheter heart valve. Key anatomical exclusion criteria were significant ascending aortopathy requiring surgical repair, an ascending aorta diameter >4.5 cm and age <60 years.

    At 30 days of follow-up after the procedure, 1.3% of patients had died or experienced a disabling stroke. Procedural success was also high at 95.3%, indicating a low complication rate. The design improvements from Evolut R to Evolut Pro, which added a sealing skirt on the bottom cells of the device, showed impressive results, with 100% of patients demonstrating mild or no aortic regurgitation within 7 days.

    Speaking about the results, Ramlawi said: “This is the first study that shows the self-expanding valve works well for patients with both type 1 and type 0 bicuspid valves. The medical community has perceived type 0 bicuspid valves as more challenging to treat, so those data are especially encouraging.”

    The trial was funded by Medtronic, maker of the self-expanding valves used in the study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details